Viral Hepatitis

Viral hepatitis is defined as liver inflammation resulting from infection by hepatotropic viruses. The disease may present as an acute infection with relatively rapid onset, or as a chronic condition that develops from long-lasting asymptomatic infection. The five primary causative agents—hepatitis A, B, C, D, and E viruses—are unrelated to one another despite sharing the clinical manifestation of hepatic inflammation. This aggregate category encompasses both foodborne and bloodborne transmission pathways with distinct clinical trajectories.

The clinical spectrum of viral hepatitis ranges from asymptomatic infection to fulminant hepatic failure. Acute presentations typically involve recent infection with relatively rapid onset of symptoms, while chronic forms may remain clinically silent for decades before progressing to decompensated liver disease. Complications of chronic viral hepatitis include cirrhosis and hepatocellular carcinoma, particularly with hepatitis B and C infections. The bloodborne viruses (B and C) are more likely to establish persistent infection compared to the enterically transmitted viruses (A and E), which are typically self-limited with complete resolution.

Viral hepatitis imposes a substantial global health burden, with approximately 1.5 million deaths recorded in 2013, the majority attributable to hepatitis B and C infections. Geographic distribution varies by virus type, with East Asia, particularly Mongolia, experiencing a disproportionately high burden of disease. The five principal hepatotropic viruses differ in their epidemiologic patterns, with hepatitis A and E associated with inadequate sanitation and hepatitis B and C concentrated in regions with limited access to safe injection practices and unscreened blood products. The relative contribution of each virus to overall morbidity and mortality varies by regional development status and public health infrastructure.

Viral hepatitis is transmitted through two primary pathways that distinguish the major causative agents. Hepatitis A and E are transmitted via the fecal-oral route, typically through consumption of contaminated food or water, and are associated with inadequate sanitation infrastructure. Hepatitis B and C are bloodborne and body fluid transmitted, with documented transmission through mother-to-child passage during birth, sexual contact involving exchange of body fluids, unsafe injection practices, and unscreened blood transfusions. The waterborne viruses generally cause acute, self-limited illness, while bloodborne viruses can establish both acute and chronic infections.

Populations at elevated risk for viral hepatitis acquisition include individuals exposed to unsafe medical practices, such as unsterile injections or unscreened blood products. Mother-to-child transmission represents a significant pathway for hepatitis B and C, particularly in settings without birth-dose vaccination or maternal viral screening. Persons engaging in behaviors involving exchange of body fluids, including unprotected sexual contact and sharing of injection equipment, face increased exposure risk. Residents of regions with inadequate sanitation infrastructure are at higher risk for hepatitis A and E infection, while East Asian populations, especially in Mongolia, experience disproportionately high hepatitis burden.

Prevention strategies for viral hepatitis differ by virus type and transmission route. Vaccines are available and effective for preventing hepatitis A and hepatitis B infections, providing immunity for extended periods following successful immunization. Hepatitis C lacks a preventive vaccine but has effective antiviral treatments available, though these therapies are associated with substantial cost that may limit accessibility in resource-constrained settings. General prevention measures include ensuring food and water safety, implementing infection control in healthcare settings, screening blood products, and promoting safe injection practices.

Surveillance for viral hepatitis must account for the distinct epidemiologic profiles of the five primary causative agents. Monitoring systems should differentiate between acute and chronic presentations, as this distinction carries implications for transmission dynamics and intervention strategies. The asymptomatic nature of chronic hepatitis B and C infection underscores the importance of laboratory-based surveillance and targeted screening in high-prevalence populations. Geographic variation in viral hepatitis burden necessitates localized surveillance approaches, particularly in regions with high rates of hepatitis B and C-related mortality.

1. 1 Wikidata. viral hepatitis.
2. 2 Wikipedia. Viral hepatitis - Wikipedia.

ICD-10

B15-B19

ICD-11

1E50

Total cases

25.0M

Total deaths

18K

Peak month

2024-03

Coverage

3 reporting countries · 2000-01-01 → 2026-05-02